Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 posted mostly high cure rates among people with genotypes 2 and 3.
Treating people with genotypes 2 and 3 of hepatitis C is cost effective in some circumstances, including among those with cirrhosis and among...
This article which originally appeared in the HCV Advocate, discusses hepatitis C genotype 2
Eight weeks of Sovaldi and GS-5816, with or without ribavirin, cured high rates of people with genotype 3 of hepatitis C, but yielded unsatisf...
Reaching an undetectable hepatitis C viral load is linked to diminished chances of liver disease and liver-related death.
Gilead’s sofosbuvir boasted high cure rates when given in combination with ribavirin to those with genotype 2 or 3 of hepatitis C.
In this week’s video, Nicholson self-injects the first of the remaining 23 Interferon injections required for his experimental Hep C genotype...
Alisporivir, a once-daily drug being developed by Novartis at the forefront of a new class of hepatitis C virus (HCV) compounds known as cyclo...
A twelve-week course of Pharmasset?s once-daily experimental nucleotide analog PSI-7977, combined with ribavirin, cured 10 of 10 people living...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.